Background Cladribine provides immunomodulation through selective targeting of lymphocyte
subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet …

Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

Neurologic involvement occurs in approximately 20% of patients with primary Sjögren syndrome
(SS). However, the diagnosis of SS with neurologic involvement is sometimes difficult, …

Background Neuromyelitis optica (NMO) is often associated with other clinical or serological
markers of non–organ-specific autoimmunity. Objective To evaluate the relationship …

Background The course and prognosis of childhood-onset multiple sclerosis have not been
well described. Methods We used data from 13 adult neurology departments affiliated with …

Background Complement is likely to have a role in refractory generalised myasthenia gravis,
but no approved therapies specifically target this system. Results from a phase 2 study …

… Patrick Vermersch has received consulting fees and/or research support from Bayer, Biogen
Idec, GlaxoSmithKline, Merck Serono, Novartis, sanofi-aventis and Teva Pharmaceuticals. …

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) is characterized by a cerebral non-atherosclerotic, non-amyloid angiopathy …

Background Most patients with multiple sclerosis without previous optic neuritis have thinner
retinal layers than healthy controls. We assessed the role of peripapillary retinal nerve fibre …

Objective To report the 5-year risk and to identify risk factors for the development of a seminal
acute or progressive clinical event in a multi-national cohort of asymptomatic subjects …